Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

621. Music therapy for people with dementia. Full Text available with Trip Pro

Music therapy for people with dementia. Dementia is a clinical syndrome with a number of different causes which is characterised by deterioration in cognitive functions. Research is pursuing a variety of promising findings for the treatment of dementia. Pharmacological interventions are available but have limited ability to treat many of the syndrome's features. Little research has been directed towards non-pharmacological treatments. In this review the evidence for music therapy as a treatment (...) is examined.To assess the effects of music therapy in the treatment of behavioural, social, cognitive and emotional problems of older people with dementia.The Cochrane Dementia and Cognitive Improvement Group (CDCIG) Specialised Register was searched on 30 June 2003 using the term "music*". This Register contains records from all major health care databases and many ongoing trial databases and is updated regularly. The principal reviewer conducted additional searches to retrieve randomised controlled trials

2004 Cochrane

622. Light therapy for managing sleep, behaviour, and mood disturbances in dementia. (Abstract)

Light therapy for managing sleep, behaviour, and mood disturbances in dementia. Rest-activity and sleep-wake cycles are controlled by the endogenous circadian rhythm generated by the suprachiasmatic nuclei (SCN) of the hypothalamus. Degenerative changes in the SCN appear to be a biological basis for circadian disturbances in people with dementia, and might be reversed by stimulation of the SCN by light.The review assesses the efficacy of bright light therapy (BLT) in managing sleep, behaviour (...) , mood, and cognitive disturbances associated with dementia.The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 27 January 2004 using the terms "bright light*", "light box*", "light visor*", "dawn-dusk*", phototherapy (MESH), phototherapy, "photo therapy", "light therapy" "light treatment", light*.All relevant, randomized controlled trials in which BLT, at any intensity and duration, was compared with a control group

2004 Cochrane

623. Respite care for people with dementia and their carers. (Abstract)

Respite care for people with dementia and their carers. Caring for someone with dementia can be emotionally and physically demanding. Respite care is any intervention designed to give rest or relief to caregivers. It is not clear what positive and negative effects the provision of respite care may have on people with dementia and their caregivers.To assess the effects of respite care for people with dementia and their caregivers, in particular the effect of respite care on rates (...) of institutionalization.The trials were identified from a last updated search of the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 2 July 2003 using the terms respite* and "day care". This Register contains up to date records from all major health care databases and many ongoing trial databases.Randomized controlled trials comparing respite care with a control intervention for people with dementia.Both reviewers carried out study selection independently and reached a consensus through

2004 Cochrane

624. SPECT for the diagnosis and assessment of dementia and Alzheimer's disease

SPECT for the diagnosis and assessment of dementia and Alzheimer's disease SPECT for the diagnosis and assessment of dementia and Alzheimer's disease SPECT for the diagnosis and assessment of dementia and Alzheimer's disease Ferrante D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ferrante D. SPECT for the diagnosis and assessment (...) of dementia and Alzheimer's disease. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' conclusions We could conclude that up until now, SPECT has not clearly demonstrated its usefulness in assessing patients with dementia, and it has no precise indications for diagnosis, evaluation of prognosis or monitoring response to treatment. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Alzheimer Disease; Dementia; Tomography, Emission

2004 Health Technology Assessment (HTA) Database.

625. Positron emission tomography, single photon emission computed tomography, computed tomography, functional magnetic resonance imaging, and magnetic resonance spectroscopy and for the diagnosis and management of Alzheimer's dementia

Positron emission tomography, single photon emission computed tomography, computed tomography, functional magnetic resonance imaging, and magnetic resonance spectroscopy and for the diagnosis and management of Alzheimer's dementia Positron emission tomography, single photon emission computed tomography, computed tomography, functional magnetic resonance imaging, and magnetic resonance spectroscopy and for the diagnosis and management of Alzheimer's dementia Positron emission tomography, single (...) photon emission computed tomography, computed tomography, functional magnetic resonance imaging, and magnetic resonance spectroscopy and for the diagnosis and management of Alzheimer's dementia Matchar DB, Kulasingam SL, Huntington A, Patwardhan M, Mann L O Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Matchar DB, Kulasingam SL, Huntington

2004 Health Technology Assessment (HTA) Database.

626. Pharmacological treatment of dementia

Pharmacological treatment of dementia Pharmacological treatment of dementia Pharmacological treatment of dementia Santaguida P, Raina P, Booker L, Patterson C, Baldassarre F, Cowan D, Gauld M, Levine M, Unsal A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Santaguida P, Raina P, Booker L, Patterson C, Baldassarre F, Cowan D, Gauld M (...) , Levine M, Unsal A. Pharmacological treatment of dementia. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 97. 2004 Authors' objectives To review the evidence and answer the questions: Does pharmacotherapy for dementia syndromes improve cognitive symptoms and outcomes? Does pharmacotherapy delay cognitive deterioration or delay disease onset of dementia syndromes? Are certain drugs, including alternative medicines (non-pharmaceutical), more

2004 Health Technology Assessment (HTA) Database.

627. Rivastigmine for dementia associated with Parkinson's disease. Full Text available with Trip Pro

Rivastigmine for dementia associated with Parkinson's disease. Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients.Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or 3 to 12 mg of rivastigmine per day for 24 weeks. Primary (...) efficacy variables. The most frequent adverse events were nausea (affecting 29.0 percent of patients in the rivastigmine group and 11.2 percent of those in the placebo group, P<0.001), vomiting (16.6 and 1.7 percent, P<0.001), and tremor (10.2 and 3.9 percent, P=0.01).In this placebo-controlled study, rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.Copyright 2004 Massachusetts Medical

2004 NEJM Controlled trial quality: predicted high

628. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. Full Text available with Trip Pro

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. The Women's Health Initiative Memory Study (WHIMS) previously found increased risk for dementia and no effect on mild cognitive impairment (MCI) in women treated with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA).To determine the effects of CEE alone and CEE plus MPA on incidence of probable dementia and MCI (...) , 1 daily tablet containing CEE (0.625 mg/d) plus MPA (2.5 mg/d) vs matching placebos.Probable dementia and MCI.In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66). Incidence rates for probable dementia in the estrogen-alone trial were statistically similar to those in the estrogen plus progestin trial (45 vs 22 per 10 000 person-years for CEE plus

2004 JAMA Controlled trial quality: predicted high

629. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia

Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

630. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review

Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

631. Pharmacological treatment of dementia

Pharmacological treatment of dementia Pharmacological treatment of dementia Pharmacological treatment of dementia Santaguida P, Raina P, Booker L, Patterson C, Baldassarre F, Cowan D, Gauld M, Levine M, Unsal A CRD summary The authors concluded that pharmacotherapy can improve cognitive symptoms and outcomes, there is some evidence for delay in disease progression, and some agents were shown to be effective in patients with vascular dementia. However, few head-to-head studies were found (...) and there were insufficient data relating to efficacy in different subgroups of patients. Despite some minor limitations, the authors' conclusions are likely to be reliable. Authors' objectives To determine the efficacy of pharmacotherapy for dementia syndromes on cognitive symptoms and outcomes. Searching The Cochrane CENTRAL Register (February 2003), MEDLINE and PREMEDLINE (1998 to February 2003), EMBASE (1998 to February 2003), AMED (1985 to February 2003), CINAHL (1982 to February 2003), AgeLine (1978

2004 DARE.

632. Management of constipation in residents with dementia: sorbitol effectiveness and cost

Management of constipation in residents with dementia: sorbitol effectiveness and cost Management of constipation in residents with dementia: sorbitol effectiveness and cost Management of constipation in residents with dementia: sorbitol effectiveness and cost Volicer L, Lane P, Panke J A, Lyman P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the therapeutic substitution of sorbitol for lactulose in the treatment of chronic constipation among nursing home residents with dementia. The doses ranged from 30 mL every other day to 6 mL twice daily. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised the residents of a dementia

2004 NHS Economic Evaluation Database.

633. Screening for delirium, dementia, and depression in older adults.

Screening for delirium, dementia, and depression in older adults. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2003 Registered Nurses' Association of Ontario

634. Healthy aging and dementia: findings from the Nun Study. (Abstract)

Healthy aging and dementia: findings from the Nun Study. The Nun Study is a longitudinal study of 678 Catholic sisters 75 to 107 years of age who are members of the School Sisters of Notre Dame congregation. Data collected for this study include early and middle-life risk factors from the convent archives, annual cognitive and physical function evaluations during old age, and postmortem neuropathologic evaluations of the participants' brains. The case histories presented include a centenarian (...) who was a model of healthy aging, a 92-year-old with dementia and clinically significant Alzheimer disease neuropathology and vascular lesions, a cognitively and physically intact centenarian with almost no neuropathology, and an 85-year-old with well-preserved cognitive and physical function despite a genetic predisposition to Alzheimer disease and an abundance of Alzheimer disease lesions. These case histories provide examples of how healthy aging and dementia relate to the degree of pathology

2003 Annals of Internal Medicine

635. Leisure activities and the risk of dementia in the elderly. Full Text available with Trip Pro

Leisure activities and the risk of dementia in the elderly. Participation in leisure activities has been associated with a lower risk of dementia. It is unclear whether increased participation in leisure activities lowers the risk of dementia or participation in leisure activities declines during the preclinical phase of dementia.We examined the relation between leisure activities and the risk of dementia in a prospective cohort of 469 subjects older than 75 years of age who resided (...) in the community and did not have dementia at base line. We examined the frequency of participation in leisure activities at enrollment and derived cognitive-activity and physical-activity scales in which the units of measure were activity-days per week. Cox proportional-hazards analysis was used to evaluate the risk of dementia according to the base-line level of participation in leisure activities, with adjustment for age, sex, educational level, presence or absence of chronic medical illnesses, and base

2003 NEJM

636. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. (Abstract)

Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Dementia is a large and growing problem but is often not diagnosed in its earlier stages. Screening and earlier treatment could reduce the burden of suffering of this syndrome.To review the evidence of benefits and harms of screening for and earlier treatment of dementia.MEDLINE, PsycINFO, EMBASE, the Cochrane Library, experts, and bibliographies of reviews.The authors developed eight (...) key questions representing a logical chain between screening and improved health outcomes, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources.Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to U.S. Preventive Services Task Force criteria.No randomized, controlled trial of screening for dementia has been completed. Brief screening tools can

2003 Annals of Internal Medicine

637. Silent brain infarcts and the risk of dementia and cognitive decline. Full Text available with Trip Pro

Silent brain infarcts and the risk of dementia and cognitive decline. Silent brain infarcts are frequently seen on magnetic resonance imaging (MRI) in healthy elderly people and may be associated with dementia and cognitive decline.We studied the association between silent brain infarcts and the risk of dementia and cognitive decline in 1015 participants of the prospective, population-based Rotterdam Scan Study, who were 60 to 90 years of age and free of dementia and stroke at base line (...) . Participants underwent neuropsychological testing and cerebral MRI at base line in 1995 to 1996 and again in 1999 to 2000 and were monitored for dementia throughout the study period. We performed Cox proportional-hazards and multiple linear-regression analyses, adjusted for age, sex, and level of education and for the presence or absence of subcortical atrophy and white-matter lesions.During 3697 person-years of follow-up (mean per person, 3.6 years), dementia developed in 30 of the 1015 participants

2003 NEJM

638. Prospective study of alcohol consumption and risk of dementia in older adults. (Abstract)

Prospective study of alcohol consumption and risk of dementia in older adults. Alcohol consumption has been associated with complex changes in cerebral vasculature and structure in older adults. How alcohol consumption affects the incidence of dementia is less clear.To determine the prospective relationship of alcohol consumption and risk of dementia among older adults.Nested case-control study of 373 cases with incident dementia and 373 controls who were among 5888 adults aged 65 years (...) and older who participated in the Cardiovascular Health Study, a prospective, population-based cohort study in 4 US communities. The controls were frequency-matched on age, death before 1999, and their attendance of a 1998-1999 clinic. Participants in this study underwent magnetic resonance imaging (MRI) of the brain and cognitive testing between 1992 and 1994 and were followed up until 1999.Odds of incident dementia, ascertained by detailed neurological and neuropsychological examinations according

2003 JAMA

639. Dementia diagnosis in developing countries: a cross-cultural validation study. (Abstract)

Dementia diagnosis in developing countries: a cross-cultural validation study. Research into dementia is needed in developing countries. Assessment of variations in disease frequency between regions might enhance our understanding of the disease, but methodological difficulties need to be addressed. We aimed to develop and test a culturally and educationally unbiased diagnostic instrument for dementia.In a multicentre study, the 10/66 Dementia Research Group interviewed 2885 people aged 60 (...) years and older in 25 centres, most in Universities, in India, China and southeast Asia, Latin America and the Caribbean, and Africa. 729 had dementia and three groups were free of dementia: 702 had depression, 694 had high education (as defined by each centre), and 760 had low education (as defined by each centre). Local clinicians diagnosed dementia and depression. An interviewer, masked to dementia diagnosis, administered the geriatric mental state, the community screening instrument for dementia

2003 Lancet

640. Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. Full Text available with Trip Pro

Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. To evaluate a simple three step procedure to identify people in the general population who are in the preclinical phase of Alzheimer's disease and dementia.Three year population based cohort study.Kungsholmen cohort, Stockholm, Sweden.1435 people aged 75-95 years without dementia.Single question asking about memory complaints, assessment by mini-mental state examination, and neuropsychological (...) testing.Alzheimer's disease and dementia at three year follow up.None of the three instruments was sufficiently predictive of Alzheimer's disease and dementia when administered separately. After participants had been screened for memory complaints and global cognitive impairment, specific tests of word recall and verbal fluency had positive predictive values for dementia of 85-100% (95% confidence intervals range from 62% to 100%). However, only 18% of future dementia cases were identified in the preclinical

2003 BMJ